Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic NK Cells with Rituximab in Refractory Lymphoid Malignancies
NCT01181258Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Aug 2010
- Primary completion
- Sep 2015
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Natural Killer Cells in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), sponsored by Masonic Cancer Center. Started Aug 2010; status: completed.
02
Drugs
Natural Killer Cells
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01181258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01181258.